Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amithiozone for MAC Pulmonary Disease
NCT00004689Phase 2Completed
- Sponsor
- National Jewish Health
- Start
- Jan 1991
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of thiacetazone in mycobacterium avium complex pulmonary disease (MAC-PD) (2 arms), sponsored by National Jewish Health. Primary endpoint: Bacteriological activity of amithiozone against MAC. Started Jan 1991; status: completed.
02
Drugs
thiacetazone
03
Conditions
mycobacterium avium complex pulmonary disease (MAC-PD)
Beyond the preview
Go deeper on NCT00004689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004689.